主要文件

查看所有文档

A7106

Azelnidipine

Name: Azelnidipine
Brand: SIGMA

≥98% (HPLC), powder

别名:

2-Amino-1,4-dihydro-6-methyl-4-(3 nitrophenyl)-3,5-pyridinedicarboxylic acid 3-[1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethyl) ester, CS-905, RS-9054

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₃₃H₃₄N₄O₆

化学文摘社编号:

123524-52-7

分子量:

582.65

NACRES:

NA.77

PubChem Substance ID:

329770914

UNSPSC Code:

12352200

MDL number:

MFCD00865803

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

Quality Level

100

assay

≥98% (HPLC)

form

powder

solubility

DMSO: >10 mg/mL

originator

Daiichi-Sankyo

storage temp.

room temp

SMILES string

CC(C)OC(=O)C1=C(C)NC(N)=C(C1c2cccc(c2)[N+]([O-])=O)C(=O)OC3CN(C3)C(c4ccccc4)c5ccccc5

InChI

1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3

InChI key

ZKFQEACEUNWPMT-UHFFFAOYSA-N

Application

Azelnidipine is a novel dihydropyridine derivative, a L-type calcium channel blocker, and an antihypertensive. Acute administration of azelnidipine prevents a sudden drop of cardiac function after acute stress. Azelnidipine may have a protective role in inflammation associated with atherosclerosis.

Biochem/physiol Actions

Azelnidipine is a L-type calcium channel blocker; antihypertensive.

Azelnidipine, a novel dihydropyridine derivative, is a L-type calcium channel blocker and antihypertensive. Unlike other L-type calcium channel blockers, azelnidipine causes minimal stimulation of the sympathetic nervous system despite its significant depressor effect. Azelnidipine may have a protective role in inflammation in atherosclerosis.

Features and Benefits

This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Daiichi-Sankyo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

GHS05,GHS07

signalword

Danger

hcodes

H302,H318

pcodes

P280 - P301 + P312 + P330 - P305 + P351 + P338 + P310

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.

Yoshio Matsui et al.

Hypertension (Dallas, Tex. : 1979), 59(6), 1132-1138 (2012-05-02)

Day-by-day home blood pressure (BP) variability (BPV) was reported to be associated with increased cardiovascular risk. We aimed to test the hypothesis that the angiotensin II receptor blocker/calcium-channel blocker combination decreases day-by-day BPV more than the angiotensin II receptor blocker/diuretic

Association of changes in ambulatory arterial stiffness index and pulse wave velocity during antihypertensive treatment: the J-CORE study.

Yoshio Matsui et al.

American journal of hypertension, 25(8), 862-868 (2012-06-01)

We aimed to investigate the association of the change in the ambulatory arterial stiffness index (AASI) with that in carotid-femoral pulse wave velocity (cfPWV) during treatment with antihypertensive medication. We enrolled 207 hypertensive patients treated with olmesartan monotherapy for 12

Hypertension in older adults: progress and limitations.

Michael W Rich

The American journal of medicine, 125(10), 949-950 (2012-08-21)

Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.

Takeshi Takami et al.

Vascular health and risk management, 7, 383-390 (2011-07-29)

The aim of this study was to compare the effects of olmesartan combined with either azelnidipine or amlodipine on central blood pressure (CBP) and left ventricular mass index (LVMI) in hypertensive patients. Patients with brachial systolic BP ≥ 140 mmHg

Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.

Ikuo Saito et al.

Journal of nephrology, 25(5), 699-708 (2011-10-25)

In the present investigation we extracted data on hypertensive patients with chronic kidney disease (CKD) who were enrolled in 3 studies - 2 studies of the angiotensin receptor blocker (ARB) olmesartan medoxomil (OLM), lasting 12 weeks and 2 years, respectively

查看所有相关文献

商品

Calcium Channels

We offers many products related to calcium channels for your research needs.

钙通道

我们提供多种与钙通道相关的产品以满足您的各类研究需求。

全球贸易项目编号

货号	GTIN
A7106-10MG	04061832960166
A7106-50MG	04061832960173

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持